Navigation Links
Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
Date:9/21/2009

SAN FRANCISCO, Sept. 21 /PRNewswire/ -- The TCT 2009 meeting will feature an unusual amount of novel information about Vulnerable Coronary Artery Plaque, the structure widely considered to be the primary cause of acute coronary events, the leading cause of death in the developed world. The concept of Vulnerable Plaque has been a topic of study for over 2 decades. TCT will showcase progress on a number of diagnostic catheters designed to identify the lipid core plaques that are widely suspected to be vulnerable.

  • Monday, September 21 -- Four presentations in the day-long Vulnerable Plaque Symposium describing the experience with LipiScan, a novel near-infrared spectroscopy catheter (InfraReDx, Inc.) approved in 2008 by the FDA for identification of lipid core plaques. (Room 131)
  • Thursday, September 24 -- Dr. Gregg Stone will present the results of the 3 year follow-up of suspected vulnerable plaques in the Prospect Trial, a study of over 700 patients with multi-vessel ultrasound (Virtual Histology, Volcano, Inc.) measurements at baseline. This major trial is the first, large, long-term study of the hypothesis that harmful vulnerable plaques can be identified before they cause a coronary event. (Room 300)

In 1989, Dr. James Muller and colleagues introduced the term "Vulnerable Plaque" to describe a plaque at high risk of disruption that leads to coronary thrombosis. Dr. Muller, CEO of InfraReDx, Inc. participated in the company's founding in 1998 for the purpose of developing a spectroscopic catheter to detect vulnerable plaque. Dr. Muller will be available at TCT to comment on the important developments related to vulnerable plaque reported at the meeting, including commentary on the outcome of the Prospect Trial. Dr. Muller and his colleague, Jim Dillon, Vice-President of Sales and Marketing at InfraReDx, Inc. will be available for comment on the use of the LipiScan system, the only FDA cleared product to detect lipid core plaque and the InfraReDx experience in over 400 patients. The commercially available LipiScan(TM) Coronary Imaging System will be displayed in the "Emerging Technologies" section at booth # 2410.

  • References
    • Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Clinical Progress Series. Circulation 1989; 79:733-743.
    • Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors, and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23:809-813.

About InfraReDx, Inc.

InfraReDx, Inc., headquartered in Burlington, Massachusetts, was founded in 1998 and is a privately-funded medical device company developing a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronary arteries. For more information, visit www.infraredx.com.

About TCT 2009

Transcatheter Cardiovascular Therapeutics (TCT) is organized by the Cardiovascular Research Foundation, which is dedicated to research and education in the broad subspecialty of interventional cardiology and endovascular medicine. TCT is scheduled from Monday, September 21(st) to Friday, September 25(th), in San Francisco, CA. at the Moscone Center. This scientific meeting is one of the world's largest events for those performing cardiac diagnostics and interventions. This meeting is the primary annual meeting for the world-wide interventional cardiology community. For more information, visit www.tctconference.com

    Company Contacts:
    Dr. Muller Contact:     Investor Contact:      Media Contact:
    Carolyn Rogers          Jeff Mazur             Jim Dillon
    InfraReDx, Inc.         InfraReDx, Inc.        InfraReDx, Inc.
    (781) 345-9644          (781) 345-9626         (781) 345-9679
    crogers@infraredx.com   jmazur@infraredx.com   jdillon@infraredx.com


'/>"/>
SOURCE InfraReDx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Web Site Will Help Pennsylvanians Learn About, Protect Against Novel H1N1 Flu
2. The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six-Fold to Over $3.2 Billion in 2018
3. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
4. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
5. Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
6. Solution to PREVENT Novel H1N1 (Swine Flu) From Closing Down Schools!
7. The Cosmetic Bootcamp LLC Announces Novel Presentations at Its 3rd Annual Marketing and Management Symposium
8. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
9. Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates
10. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
11. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has ... Dr. Talei has come up with a proprietary technique that he calls the ... that have dropped. For all ages, patients can expect to look refreshed, rejuvenated, and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will host ... , The two-day conference is focused on advancing scientific knowledge about the aggressive ... and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” ...
(Date:6/23/2017)... , ... June 23, 2017 , ... MD Now ... This is MD Now’s 28th facility overall and marks the urgent care center's eighth ... one mile North of The Falls shopping mall. The new clinic offers a wide ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
(Date:6/5/2017)... CINCINNATI , June 5, 2017 The ... a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been ... Cincinnati Enquirer . Results are based on ... specializing in organizational health and workplace improvement. The survey measures ... ...
(Date:6/1/2017)... June 1, 2017 Nutriceutical Holdings (NH), parent ... Solutions (VRS), and KD Pharma Group have decided to ... by KD Pharma Group. KD Pharma Group will become ... to acquire the entire company. "We believe ... are committed to growing the NH companies by providing ...
Breaking Medicine Technology: